Efficacy of polymyxin B against different pathogens in carbapenem-resistant gram-negative bacterial pneumonia and its relationship with alveolar epithelial lining fluid concentration: a prospective cohort study
- 1Department of Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, P.R. China
- 2Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, P.R. China
- 3Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, P.R. China
Abstract
Background The relationship between polymyxin B (PMB) concentrations in alveolar epithelial lining fluid (ELF) and pathogen clearance in carbapenem-resistant Gram-negative bacilli (CRGNB) pneumonia remains unclear. This study evaluated the efficacy of combined nebulized and intravenous PMB and its association with ELF exposure.Methods This prospective cohort study included 104 patients with CRGNB pneumonia caused by Pseudomonas aeruginosa (CRPA, n=34), Acinetobacter baumannii (CRAB, n=38), and Klebsiella pneumoniae (CRKP, n=32) receiving nebulized PMB (25 mg every 12 h) plus intravenous PMB (1.25 mg/kg every 12 h) for approximately 14 days. PMB ELF concentrations were measured by the urea dilution method. The primary outcome was bacterial clearance rate; secondary outcomes included time to bacterial clearance, clinical efficacy, fever normalization, 28-day survival, CRGNB-related mortality, inflammatory markers and adverse events.Results Bacterial clearance rates (70.59% CRPA, 71.05% CRAB, 78.12% CRKP) and clinical efficacy rates (70.59%, 81.58%, 78.12%) showed no significant intergroup differences (all p > .05). CRKP had a shorter time to clearance than CRAB (median, 5.00 vs. 7.00 days, p = .004). No significant differences were observed in 28-day survival, CRGNB-related mortality, or adverse events. PMB ELF trough concentration and mechanical ventilation duration were independent predictors of bacterial clearance (both p < .05). Higher PMB ELF peak and trough concentrations were associated with shorter clearance/replacement time (both p < .05).Conclusion The combined PMB regimen achieves favorable bacterial clearance and clinical efficacy in CRGNB pneumonia. Higher local pulmonary PMB exposure was associated with improved bacteriological outcomes, supporting ELF-guided dose optimization.
Related
- Optimizing Polymyxin B Exposure in Carbapenem-Resistant Organism-Associated Hospital-Acquired Pneumonia: A Retrospective Observational Study.
- The relationship between hemoglobin concentration and mortality in patients receiving venovenous extracorporeal membrane oxygenation support: a single-center retrospective cohort study
- Prevalence, acquisition, and risk factors of carbapenem-resistant enterobacterales colonization in long-term care hospitals: A prospective active surveillance study
- Associations of high-density lipoprotein cholesterol concentration and particle count with mortality: a prospective study of 50,000 men and 100,000 women
- Population Pharmacokinetics and Model-Informed Precision Dosing of Colistin Sulfate in Critically Ill Patients with Carbapenem-Resistant Gram-Negative Infections: A Prospective Pharmacokinetic-Pharmacodynamic Study.
BibTeX
@article{huang2026efficacy,
title = {{Efficacy of polymyxin B against different pathogens in carbapenem-resistant gram-negative bacterial pneumonia and its relationship with alveolar epithelial lining fluid concentration: a prospective cohort study}},
author = {Xuanxi Huang and Mengjie Song and Xueyong Li and Qiong Wu and Wanru Li and Hongqiang Qiu and Wenwei Wu and Hui Zhang and Yu Cheng and Lili Zhou},
journal = {Annals of Medicine},
year = {2026},
month = nov,
doi = {10.1080/07853890.2026.2752633},
url = {https://doi.org/10.1080/07853890.2026.2752633},
note = {CC BY},
}
RIS
TY - JOUR
TI - Efficacy of polymyxin B against different pathogens in carbapenem-resistant gram-negative bacterial pneumonia and its relationship with alveolar epithelial lining fluid concentration: a prospective cohort study
AU - Xuanxi Huang
AU - Mengjie Song
AU - Xueyong Li
AU - Qiong Wu
AU - Wanru Li
AU - Hongqiang Qiu
AU - Wenwei Wu
AU - Hui Zhang
AU - Yu Cheng
AU - Lili Zhou
PY - 2026
DA - 2026/11/04
JO - Annals of Medicine
DO - 10.1080/07853890.2026.2752633
UR - https://doi.org/10.1080/07853890.2026.2752633
AB - Background The relationship between polymyxin B (PMB) concentrations in alveolar epithelial lining fluid (ELF) and pathogen clearance in carbapenem-resistant Gram-negative bacilli (CRGNB) pneumonia remains unclear. This study evaluated the efficacy of combined nebulized and intravenous PMB and its association with ELF exposure.Methods This prospective cohort study included 104 patients with CRGNB pneumonia caused by Pseudomonas aeruginosa (CRPA, n=34), Acinetobacter baumannii (CRAB, n=38), and Klebsiella pneumoniae (CRKP, n=32) receiving nebulized PMB (25 mg every 12 h) plus intravenous PMB (1.25 mg/kg every 12 h) for approximately 14 days. PMB ELF concentrations were measured by the urea dilution method. The primary outcome was bacterial clearance rate; secondary outcomes included time to bacterial clearance, clinical efficacy, fever normalization, 28-day survival, CRGNB-related mortality, inflammatory markers and adverse events.Results Bacterial clearance rates (70.59% CRPA, 71.05% CRAB, 78.12% CRKP) and clinical efficacy rates (70.59%, 81.58%, 78.12%) showed no significant intergroup differences (all p > .05). CRKP had a shorter time to clearance than CRAB (median, 5.00 vs. 7.00 days, p = .004). No significant differences were observed in 28-day survival, CRGNB-related mortality, or adverse events. PMB ELF trough concentration and mechanical ventilation duration were independent predictors of bacterial clearance (both p < .05). Higher PMB ELF peak and trough concentrations were associated with shorter clearance/replacement time (both p < .05).Conclusion The combined PMB regimen achieves favorable bacterial clearance and clinical efficacy in CRGNB pneumonia. Higher local pulmonary PMB exposure was associated with improved bacteriological outcomes, supporting ELF-guided dose optimization.
SN - 1365-2060
SN - 0785-3890
ER -